Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLURE secukinumab pre-filled syringe study in moderate to severe plaque psoriasis
2015-005170-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab 300 mg with Placebo (2 arms). Primary endpoints: PASI 75 response at Week 12 and IGA mod 2011 0 or 1 response at Week 12. Started Jul 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-005170-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005170-38.